{"id":"NCT01246479","sponsor":"Valneva Austria GmbH","briefTitle":"Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study","officialTitle":"Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-10","completion":"2014-09","firstPosted":"2010-11-23","resultsPosted":"2015-04-29","lastUpdate":"2020-03-18"},"enrollment":23,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"PROCEDURE","name":"Blood draw","otherNames":[]},{"type":"BIOLOGICAL","name":"IC51 has given in the parent study IC51-322","otherNames":[]}],"arms":[{"label":"No treatment","type":"OTHER"}],"summary":"The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.","primaryOutcome":{"measure":"Rate of Subjects With PRNT50 Titers of ≥ 1:10 at Month 12 After the First IC51 Vaccination (in Study IC51-322)","timeFrame":"Month 12","effectByArm":[{"arm":"No Treatment","deltaMin":89.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":5,"countries":["United States","Australia","Germany"]},"refs":{"pmids":["32156630"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":23},"commonTop":["Otitis media acute","Pharyngitis streptococcal","Diarrhoea","Skin papilloma"]}}